Navigation Links
Golden Seeds Invests In DxUpClose, Disruptive Technology That Performs An Antibiotic Sensitivity Test At The Patient's Bedside In Less Than An Hour
Date:8/15/2012

DALLAS, Aug. 15, 2012 /PRNewswire/ -- Golden Seeds has invested in a $1.0M Series A financing of DxUpClose. DxUpClose is developing an in-vitro antibiotic sensitivity test for use at point-of-care, designed to deliver results in less than an hour. The first target market is urinary tract infections. Physicians currently do not have real time tools to test antibiotics against bacteria so they have to guess or order expensive lab tests which take 24 to 48 hours for results. Without lab tests, 10% of the time the wrong antibiotic is prescribed. This causes $2.7 billion per year in unnecessary costs due to misdiagnosis and acerbates the growing antibiotic resistance problem. In less than an hour, this bedside test could reduce the guess work and give better results to millions of patients.

The product personalizes medicine by doing three things within one hour at the patient's bedside: list antibiotics proven to be effective against the bacteria, screen for deadly bacteria, and count bacteria present.  The electronic sensor is designed to withstand hot and cold shipping conditions, weigh less than 16 oz and run on batteries.   

"This funding will help us complete the development of the product, enhance sensitivity of the diagnostic, and achieve FDA's design verification milestone" said Cyndi Nickel, DxUpClose's CEO.

"DxUpClose will bring a state of the art diagnostic solution to sufferers of a very painful illness, reduce healthcare costs and assist doctors in providing the best healthcare to their patients", said Jan Norton, Managing Director, Golden Seeds, who co-led the financing and joins the company's board as an observer.

About DxUpClose
DxUpClose was founded in 2009 by Cyndi Nickel, former Hewlett Packard executive in cutting edge technologies.  She combines her business acumen with researchers, inventors and patents from both Texas A&M University and Texas State University to develop a state of the art solution by personalizing medicine to solve a common problem.

About Golden Seeds
Golden Seeds is an investment firm dedicated to delivering above market returns for investors through the empowerment of women entrepreneurs and the people who invest in them. Its angel network consisting of 250 men and women is the fourth largest in the US and was the third most active in terms of deals done in 2011.

CONTACT
Lou Peralta
888-629-6774 x561


'/>"/>
SOURCE Golden Seeds
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Meditech Holdings Limited Announces 2011/ 2012 Annual Results
2. Sentry BioPharma Services Invests in Global Clinical Supply Services with -45C Freezer Expansion
3. Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award
4. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
5. Global Chiral Technology Industry
6. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
7. Elekta Technology at Work in 100 Percent of Americas Top Cancer Hospitals
8. Survey: Hospital Executives Nationwide Facing Operating Room Case Volume Increases, Seeking Greater Efficiency through Healthcare Information Technology (HIT)
9. Global Information Inc Offers Big Discounts on Market Forecasts for Surgical Sealants, Wound Closure Products, Spine Surgery Technology, and More
10. Leading Medical Technology Company Selects inContact to Transform Service Experience
11. Kam Aims Uses Cloud Technology to Bring Affordable Solution to Freestanding Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... -- OrthoAccel ® Technologies, Inc. announces that the ... Effect of Vibration on Molar Distalization," a study that ... Jay Bowman , this prospective, peer-reviewed clinical study concluded ... ® speeds up molar distalization rates in the ... days to move the upper molars into a normal, ...
(Date:1/17/2017)... 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene therapy ... president, research and pharmaceutical development at Tocagen, will present at ... Jan. 17-20 in Miami . ... ... for replicating viruses - what to do when and why Date ...
(Date:1/17/2017)... Jan. 17, 2017  EMD Serono, the biopharmaceutical business ... in the U.S. and Canada , ... joined the company as Senior Vice President and Head ... Smith will oversee the Fertility and Endocrinology businesses in ... launched its first product last year with Gidget™, a ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate its ... Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center in ... the gold standard for high-definition, in-ear earphones. This classic earphone has been updated ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting ... Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted ... providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare ... blind clinical study for its dental gel that shows significant reduction in plaque levels ... containing triclosan. The study was conducted at the Beckman Laser Institute at UC Irvine ...
Breaking Medicine News(10 mins):